Trial intelligence / Profile preview

Moxifloxacin prophylaxis for bacteremia after high-dose chemotherapy and autologous peripheral stem cell transplantation

2005-003271-21Phase 3Completed

Sponsor: University of Cologne
Start: May 2006
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, randomised, double-blind trial in Bacteremia comparing Moxifloxacin prophylaxis with Placebo (2 arms). Primary endpoint: Clinically significant bacteremia. Started May 2006; status: completed.

Drugs

moxifloxacin

Conditions

Bacteremia

Beyond the preview

Go deeper on 2005-003271-21.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2005-003271-21.